FDA Webview
X
about-us-banner

Pay Per View

Home / Pay Per View

Lilly's Oral GLP-1 Outperforms Oral Semaglutide in Diabetes Trial

[ Price : $8.95]

Eli Lilly reports Phase 3 study results showing its oral GLP-1 receptor agonist Foundayo (orforglipron) outperformed Novo Nordisk'...

AMA Delegates Call for Tighter FDA Oversight of Unapproved Peptides

[ Price : $8.95]

Delegates at the American Medical Association's annual meeting vote to support stronger FDA oversight of synthetic peptide product...

Clinical Hold on Quantum IND

[ Price : $8.95]

FDA places a clinical hold on Quantum BioPharmas IND for its multiple sclerosis drug candidate Lucid-21-302.

Induced Infringement Decision Analyzed

[ Price : $8.95]

Eight Mintz attorneys analyze the recent Supreme Court decision giving generic drug manufacturers a victory in an induced infringe...

FDA AI Inspections Prompts Industry Readiness Strategy Rethink

[ Price : $8.95]

Former FDA enforcement official suggests new strategies for industry to prepare for agency inspections that rely on artificial int...

Agency Defends Generic Drug Oversight

[ Price : $8.95]

FDA officials are seeking to bolster confidence in generic medicines, highlighting the agency's oversight of drug manufacturing, i...

FDA Seeks Industry Data for Kidney Biomarker Initiative

[ Price : $8.95]

FDA launches a new effort to aggregate clinical trial data on kidney safety biomarkers, seeking pharmaceutical industry participat...

Alert on GE HealthCare Infant Resuscitation Systems

[ Price : $8.95]

FDA issues an early alert warning healthcare providers about a potentially high-risk defect affecting certain infant resuscitation...

PhRMA Urges FDA to Clarify Digital Health Technology Standards

[ Price : $8.95]

PhRMA calls on FDA to provide clearer regulatory expectations for the use of digital health technologies in drug development, argu...

FDA Expands Pfizer Bleeding Drug Approval

[ Price : $8.95]

FDA approves an expanded indication for Pfizer's hemophilia treatment Hympavzi (marstacimab-hncq), allowing its use in additional ...